Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Revance Therapeutics

Revance Therapeutics reported $547.8M in Assets for its fiscal quarter ending in March of 2023.

Assets Change
Cara Therapeutics CARA:US USD 153.28M 28.96M
Coherus Biosciences CHRS:US USD 402.43M 78.42M
Eli Lilly LLY:US USD 53.16B 3.67B
Endo International ENDP:US USD 5.57B 191.83M
Horizon Pharma HZNP:US USD 8.99B 121.17M
J&J JNJ:US USD 195.97B 8.59B
Neurocrine Biosciences NBIX:US USD 2.36B 8.9M
P&G PG:US USD 119.85B 2.14B
Pacira PCRX:US USD 1.52B 157.78M
Revance Therapeutics RVNC:US USD 547.8M 34.1M
Supernus Pharmaceuticals SUPN:US USD 1.79B 89.3M